Aurisco and CDMO (contract development and manufacturing organization) in China, is cooperating with Cytiva, a global science leader, to build its first Oligo FlexFactory platform for commercial production. Enabled with better speed and efficiency, Aurisco will deliver more oligonucleotides and better serve its customers around the world. The Oligo FlexFactory platform is the first of the three planned commercial manufacturing lines of Aurisco in Yangzhou of East China.

And this whole manufacturing site is expected to produce 200 kilograms of oligonucleotides every year. During this cooperation, Cytiva will offer a comprehensive enterprise solution to Aurisco. It includes an Oligo FlexFactory GMP platform and various technical and service support, such as talent training, process design of the manufacturing site, as well as life-cycle project management.

It's not the first time Aurisco has collaborated with Cytiva. Previously, with the support of Cytiva's products and service, Aurisco has launched oligonucleotide CRO (contract research organization) and CDMO services of laboratory and pilot scales in Shanghai. In the future, Aurisco and Cytiva will look into more cooperative opportunities, accelerating the delivery of life-changing medicines to more patients.